PT - JOURNAL ARTICLE AU - Alberto Aleta AU - David Martín-Corral AU - Michiel A. Bakker AU - Ana Pastore y Piontti AU - Marco Ajelli AU - Maria Litvinova AU - Matteo Chinazzi AU - Natalie E. Dean AU - M. Elizabeth Halloran AU - Ira M. Longini, Jr. AU - Alex Pentland AU - Alessandro Vespignani AU - Yamir Moreno AU - Esteban Moro TI - Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas AID - 10.1101/2020.12.15.20248273 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.15.20248273 4099 - http://medrxiv.org/content/early/2020/12/17/2020.12.15.20248273.short 4100 - http://medrxiv.org/content/early/2020/12/17/2020.12.15.20248273.full AB - Detailed characterizations of SARS-CoV-2 transmission risk across different social settings can inform the design of targeted and less disruptive non-pharmaceutical interventions (NPI), yet these data have been lacking. Here we integrate real-time, anonymous and privacy-enhanced geolocalized mobility data with census and demographic data in the New York City and Seattle metropolitan areas to build a detailed agent-based model of SARS-CoV-2 transmission. The aim is to estimate where, when, and how many transmission events happened in those urban areas during the first wave of the pandemic. We estimate that most infections (80%) are produced by a small number of people (27%), and that about 10% of events can be considered super-spreading events (SSEs), i.e. generating more than eight secondary infections. Although mass gatherings present an important risk for future SSEs, we find that the bulk of transmission in the first wave occurred in smaller events at settings like workplaces, grocery stores, or food venues. We also observe that places where the majority of transmission and SSEs happened changed during the pandemic and are different across cities, a signal of the large underlying behavioral component underneath them. Our results demonstrate that constant real-time tracking of transmission events is needed to create, evaluate, and refine more effective and localized measures to contain the pandemic.Competing Interest StatementM.E.H. reports grants from the National Institute of General Medical Sciences during the conduct of the study; M.A. received research funding from Seqirus; A.V. reports grants and personal fees from Metabiota, Inc., outside of the submitted work; M.C. and A.PyP report grants from Metabiota, Inc., outside of the submitted work. The authors declare no other relationships or activities that could appear to have influenced the submitted work.Funding StatementN.E.D., I.M.L., MEH, A.PyP. and A.V. acknowledge the support of NIH/NIAID R56-AI148284. M.C. and A.V. acknowledge support from Google Cloud Healthcare and Life Sciences Solutions via the GCP research credits program. E.M. acknowledges partial support by MINECO (FIS2016-78904-C3-3-P and PID2019-106811GB-C32). Y.M. acknowledges partial support from the Government of Aragon and FEDER funds, Spain through grant E36-20R (FENOL), and by MINECO and FEDER funds (FIS2017-87519-P). A.A. and Y.M. acknowledge support from Banco Santander (Santander-UZ 2020/0274) and Intesa Sanpaolo Innovation Center. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MIT Committee on the Use of Humans as Experimental Subjects. COUHES Exemption number #1812635935All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study is available from Cuebiq through their COVI19 collaborative, but restrictions apply to the availability of these data, which were used under licenses for the current study, and so are not publicly available. Aggregated data used in the models are however available from the authors upon reasonable request and permission of Cuebiq. Other data used comes from the American Community Survey (5-year) from the Census.